A treatment selection strategy combines whole exome sequencing of tumor and non-tumor tissues with fruit fly models to identify effective drug combinations for cancer patients, assessing over 1,200 FDA-approved drugs. This comprehensive drug screening service aims to improve treatment recommendations based on individual genetic profiles.